This site is intended for healthcare professionals
News

REACH3 study shows Jakavi significantly improves outcomes in patients with steroid-refractory/dependent chronic graft-versus-host disease. Incyte + Novartis.

Read time: 2 mins
Last updated:7th Dec 2020
Published:7th Dec 2020
Condition: Graft-v-Host Disease (GvHD)
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest